Revolution Medicines

Revolution Medicines is a clinical-stage oncology company focused on developing novel targeted therapies for RAS-addicted cancers. Their mission is to revolutionize treatment for patients with these cancers by discovering, developing, and delivering innovative, targeted medicines. The company has a deep pipeline of RAS(ON) inhibitors, which are designed to suppress diverse oncogenic variants of RAS proteins. They also develop RAS companion inhibitors for use in combination treatment strategies.

Revolution Medicines is committed to transformative science and values cross-functional collaboration, creating a diverse and inclusive team environment. Their tri-complex inhibitor platform is a revolutionary technology that enables unprecedented access to the active form of oncogenic RAS. They are also committed to patients and offer a competitive total rewards package for their employees, including an equity program, comprehensive time-off policies, and subsidized on-site amenities.

Revolution Medicines offers a hybrid work model, allowing employees to work both on-site and remotely. Their on-site culture is described as collaborative and inclusive with opportunities for professional development through internal programs like Lunch & Learns, RevMasters, and RevMed Annual Research Day. The company also provides a comprehensive leadership development program for early-career leaders and recognizes the importance of a diverse and inclusive team.

Revolution Medicines offers a competitive benefits package designed to attract and retain top talent. The company provides employees with an equity program including stock options and restricted stock units, a comprehensive time-off policy, subsidized on-site café, paid parental leave, an employee stock purchase plan, commuting benefits and shuttle service, a choice of medical, dental and vision insurance programs, mental health and well-being programs, a 401(k) plan with a company match, complimentary electric vehicle charging stations, and an on-site fitness center.

Revolution Medicines is a clinical-stage oncology company focused on developing innovative, targeted therapies for patients living with RAS-addicted cancers, which account for 30% of all new human cancer diagnoses. Their mission is to revolutionize treatment for these patients by discovering, developing, and delivering novel medicines that target the previously undruggable RAS proteins. They are pioneering a new approach to treating RAS-addicted cancers by using their revolutionary tri-complex inhibitor platform to directly inhibit the active form of oncogenic RAS.

Revolution Medicines fosters a culture centered around innovation, collaboration, and a tireless commitment to improving the lives of patients with RAS-addicted cancers. They value diversity, inclusivity, and integrity in all aspects of their work, creating an environment where every employee feels empowered to contribute and make a difference. Their culture champions a collaborative spirit, encouraging cross-functional teamwork and the sharing of diverse perspectives. They are committed to professional development, offering opportunities for their team members to learn and grow, fostering a culture of learning and continuous improvement.

Revolution Medicines prioritizes inclusiveness and fairness, recognizing the value of diverse perspectives, experience, and backgrounds. They strive to create an equitable work environment where all team members feel respected and valued, contributing to their shared mission of revolutionizing treatment for patients with RAS-addicted cancers. They actively work to increase the diversity of their candidate pool and support local and national non-profit organizations to expand opportunities for underrepresented communities in the life sciences sector.